Xinafoate salt of N4-[(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-N2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine

Details for Australian Patent Application No. 2008294473 (hide)

Owner Pfizer Limited

Inventors Taylor, Stefan Colin John

Agent Allens Arthur Robinson

Pub. Number AU-A-2008294473

PCT Pub. Number WO2009/031011

Priority 60/970,030 05.09.07 US

Filing date 27 August 2008

Wipo publication date 12 March 2009

International Classifications

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/538 (2006.01)

A61P 11/06 (2006.01) Drugs for disorders of the respiratory system

Event Publications

11 March 2010 PCT application entered the National Phase

  PCT publication WO2009/031011 Priority application(s): WO2009/031011

8 April 2010 Amendment Made

  The nature of the amendment is: Amend the invention title to read Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one) - 6-yl]-5-fluoro-N2-[3-methylaminocar-bonylmethyleneoxy)phenyl]-2,4-pyr imidinediamine

14 July 2011 Assignment before Grant

  Pfizer Limited The application has been assigned to Rigel Pharmaceuticals, Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008294478-An energy generating system using a plurality of waterwheels

2008294472-Fastening tool for fastening different length elements